Last updated on May 2019

Survey Study for Velaglucerase Alfa (VPRIV) in Japan

Brief description of study

The objective of this post-marketing survey study is to collect data to determine the safety and efficacy of velaglucerase alfa (VPRIV) in participants with Gaucher disease who are new to therapy or have been switched from another therapeutic agent for Gaucher disease.

Clinical Study Identifier: NCT03625882

Find a site near you

Start Over


Kyoto, Japan
  Connect »